Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer

Abstract excerpt

BACKGROUND: germline mutation-associated early breast cancer. METHODS: germline pathogenic or likely pathogenic variants and high-risk clinicopathological factors who had received local treatment and neoadjuvant or adjuvant chemotherapy. Patients were randomly assigned (in a 1:1 ratio) to 1 year of oral olaparib or placebo. The primary end point was invasive disease-free survival. RESULTS: A total of 1836...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Advanced Breast Cancer Therapies
• Share to BRCA gene mutations in cancer
• Share to PARP inhibition in cancer therapy